Johnson & Johnson: A Strong Healthcare Stock for Stability
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2026
0mins
Source: Fool
- Resilience in Downturns: Johnson & Johnson's essential pharmaceutical and medical device products ensure high demand even during economic downturns, providing stability and making it a reliable stock during market crashes.
- Solid Financial Health: The company boasts an AAA credit rating from S&P Global, which is higher than that of the U.S. government, indicating its ability to meet financial obligations during crises, thereby boosting investor confidence.
- Dividend King Status: With 64 consecutive years of dividend increases, Johnson & Johnson demonstrates a robust business foundation, and its regular payouts can help mitigate losses during market downturns, attracting income-focused investors.
- Future Growth Outlook: Despite facing legal challenges and potential government price negotiations, Johnson & Johnson anticipates a 7% year-over-year sales growth to $100.8 billion by 2026, showcasing its strong growth potential even amidst adversity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 228.170
Low
190.00
Averages
218.50
High
240.00
Current: 228.170
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson: A Reliable Dividend King Amidst Challenges
- Consistent Dividend Growth: Johnson & Johnson has increased its dividend for 64 consecutive years, making it the only Dividend King in the healthcare sector, demonstrating its stability and strong business model amidst economic fluctuations.
- Legal Challenges Management: Despite facing legal issues related to talcum powder, J&J continues to reward investors with dividends, reflecting its resilience in adversity and commitment to shareholders.
- Financial Health: With a dividend payout ratio of approximately 60% and a debt-to-equity ratio of 0.7, J&J shows solid financial health, covering interest costs 15 times, indicating low risk for its dividends.
- Long-Term Growth Potential: Over the past decade, J&J's revenues have grown at an annualized rate of 3%, while earnings have increased by about 7%, showcasing its ability to provide stable growth over the long term, making it an attractive option for dividend investors seeking safe investments.
See More
Johnson & Johnson: Strong Dividends Amid Market Challenges
- Stable Dividend Growth: Johnson & Johnson has increased its dividend for 64 consecutive years, earning the title of Dividend King, showcasing strong business resilience despite public challenges like legal issues related to talcum powder, which attracts long-term investor interest.
- Clear Market Positioning: Following the spin-off of its consumer products business, J&J focuses on pharmaceuticals and medical devices, ensuring its dominant position in the non-discretionary healthcare spending market, further solidifying its core competitiveness.
- Strong Financial Health: With a dividend payout ratio of approximately 60% and a debt-to-equity ratio of 0.7, alongside an interest coverage ratio of 15 times, J&J demonstrates financial robustness amid economic uncertainties, indicating minimal risk to its dividends.
- Long-Term Growth Potential: Although current valuations exceed five-year averages, J&J's revenue and earnings growth rates are 3% and 7% respectively, with a dividend growth rate of about 6%, providing an attractive option for dividend investors seeking safe investments amid inflationary pressures.
See More
Markel Group Q4 2025 Earnings Beat Estimates Significantly
- Strong Earnings Report: Markel Group reported Q4 2025 EPS of $48.75, significantly exceeding the expected $25.73, demonstrating robust profitability under its insurance float model and reinforcing its competitive position in the market.
- Operating Income Growth: In 2025, Markel achieved operating income of $3.2 billion, with adjusted operating income surpassing $2.3 billion, indicating solid growth across all reportable segments and highlighting the company's operational strength.
- Increased Shareholder Returns: Markel repurchased $429.5 million in shares during Q4 2025, with shareholders' equity reaching $18.6 billion, reflecting the company's commitment to shareholder returns and its strong cash flow and capital allocation capabilities.
- Improved Combined Ratio: The combined ratio improved from 95.5% to 94.6%, indicating effective risk management and cost control, which enhances the company's long-term profitability and market appeal.
See More
Jury Rules Johnson & Johnson Not Negligent in Talc Case
- Jury Verdict: A Los Angeles jury ruled that Johnson & Johnson was not negligent in selling its talc-based cosmetic powder, with 10 out of 12 jurors siding with the company, a significant outcome amid tens of thousands of lawsuits.
- Lawsuit Context: The lawsuit was brought by the families of three women who allegedly died from ovarian cancer after using J&J's talc products, with the company's litigation VP asserting that the claims were based on 'junk science', indicating a strong defense strategy.
- Legal Challenges: Despite this victory, J&J continues to face numerous lawsuits claiming its talc products caused ovarian cancer, and previous attempts to settle through bankruptcy have failed, highlighting ongoing legal risks.
- Historical Litigation: J&J has resolved most lawsuits related to mesothelioma, a rare cancer linked to asbestos exposure, with nearly all remaining cases focused on ovarian cancer claims, underscoring the complexity and challenges the company faces in legal matters.
See More
US Stocks Retreat as Tech Sector Faces Pressure
- Job Data Impact: Non-farm payrolls rose by 172,000 in May, exceeding expectations, while the unemployment rate held steady at 4.3%, leading to increased Treasury yields and heightened market expectations for a rate hike, negatively impacting stocks.
- Chip Stock Investment Opportunity: Jim Cramer highlighted that despite the tech sector's pullback, this presents a good opportunity to buy chip stocks, particularly Intel, which fell 6% on Friday, indicating that confidence in the sector remains strong.
- CrowdStrike Stock Decline: CrowdStrike's stock fell another 3.4% on Friday, with the CEO stating that expectations for earnings boosts from Anthropic's AI model are premature; Jim believes this pullback offers a buying opportunity for new investors, anticipating significant growth this quarter.
- Upcoming IPOs: SpaceX's IPO is set for next Friday, and although the S&P announced no index adjustments, Jim remains cautious about investors potentially selling existing holdings to make room for SpaceX, especially with Anthropic and OpenAI IPOs also on the horizon.
See More
Alvotech Resubmits U.S. Biosimilar Applications for AVT05 and AVT06
- Stock Surge: Alvotech (ALVO) shares spiked on Thursday following the company's announcement of the resubmission of U.S. marketing applications for biosimilars targeting Johnson & Johnson's (JNJ) Simponi and Regeneron's (REGN) Eylea, reflecting market optimism about its product prospects.
- Product Positioning: AVT05 is designed as an off-patent version of JNJ's arthritis therapy for both subcutaneous and intravenous administration, while AVT06 targets Regeneron's blockbuster eye therapy Eylea (aflibercept) 2 mg, indicating Alvotech's strategic positioning in the biopharmaceutical sector.
- Application Resubmission Context: The FDA previously denied the Biologics License Applications (BLA) for AVT05 and AVT06 due to manufacturing concerns, and the resubmission includes responses to an FDA Post-Application Action Letter and results from an FDA inspection completed in May 2026, demonstrating the company's commitment to compliance.
- Review Expectations: The resubmitted BLAs are expected to undergo a six-month review by the FDA, and a successful outcome could potentially open the U.S. market for Alvotech, further enhancing its growth potential in the biosimilar sector.
See More
Johnson & Johnson: A Reliable Dividend King Amidst Challenges
- Consistent Dividend Growth: Johnson & Johnson has increased its dividend for 64 consecutive years, making it the only Dividend King in the healthcare sector, demonstrating its stability and strong business model amidst economic fluctuations.
- Legal Challenges Management: Despite facing legal issues related to talcum powder, J&J continues to reward investors with dividends, reflecting its resilience in adversity and commitment to shareholders.
- Financial Health: With a dividend payout ratio of approximately 60% and a debt-to-equity ratio of 0.7, J&J shows solid financial health, covering interest costs 15 times, indicating low risk for its dividends.
- Long-Term Growth Potential: Over the past decade, J&J's revenues have grown at an annualized rate of 3%, while earnings have increased by about 7%, showcasing its ability to provide stable growth over the long term, making it an attractive option for dividend investors seeking safe investments.
See More
Johnson & Johnson: Strong Dividends Amid Market Challenges
- Stable Dividend Growth: Johnson & Johnson has increased its dividend for 64 consecutive years, earning the title of Dividend King, showcasing strong business resilience despite public challenges like legal issues related to talcum powder, which attracts long-term investor interest.
- Clear Market Positioning: Following the spin-off of its consumer products business, J&J focuses on pharmaceuticals and medical devices, ensuring its dominant position in the non-discretionary healthcare spending market, further solidifying its core competitiveness.
- Strong Financial Health: With a dividend payout ratio of approximately 60% and a debt-to-equity ratio of 0.7, alongside an interest coverage ratio of 15 times, J&J demonstrates financial robustness amid economic uncertainties, indicating minimal risk to its dividends.
- Long-Term Growth Potential: Although current valuations exceed five-year averages, J&J's revenue and earnings growth rates are 3% and 7% respectively, with a dividend growth rate of about 6%, providing an attractive option for dividend investors seeking safe investments amid inflationary pressures.
See More
Markel Group Q4 2025 Earnings Beat Estimates Significantly
- Strong Earnings Report: Markel Group reported Q4 2025 EPS of $48.75, significantly exceeding the expected $25.73, demonstrating robust profitability under its insurance float model and reinforcing its competitive position in the market.
- Operating Income Growth: In 2025, Markel achieved operating income of $3.2 billion, with adjusted operating income surpassing $2.3 billion, indicating solid growth across all reportable segments and highlighting the company's operational strength.
- Increased Shareholder Returns: Markel repurchased $429.5 million in shares during Q4 2025, with shareholders' equity reaching $18.6 billion, reflecting the company's commitment to shareholder returns and its strong cash flow and capital allocation capabilities.
- Improved Combined Ratio: The combined ratio improved from 95.5% to 94.6%, indicating effective risk management and cost control, which enhances the company's long-term profitability and market appeal.
See More
Jury Rules Johnson & Johnson Not Negligent in Talc Case
- Jury Verdict: A Los Angeles jury ruled that Johnson & Johnson was not negligent in selling its talc-based cosmetic powder, with 10 out of 12 jurors siding with the company, a significant outcome amid tens of thousands of lawsuits.
- Lawsuit Context: The lawsuit was brought by the families of three women who allegedly died from ovarian cancer after using J&J's talc products, with the company's litigation VP asserting that the claims were based on 'junk science', indicating a strong defense strategy.
- Legal Challenges: Despite this victory, J&J continues to face numerous lawsuits claiming its talc products caused ovarian cancer, and previous attempts to settle through bankruptcy have failed, highlighting ongoing legal risks.
- Historical Litigation: J&J has resolved most lawsuits related to mesothelioma, a rare cancer linked to asbestos exposure, with nearly all remaining cases focused on ovarian cancer claims, underscoring the complexity and challenges the company faces in legal matters.
See More
US Stocks Retreat as Tech Sector Faces Pressure
- Job Data Impact: Non-farm payrolls rose by 172,000 in May, exceeding expectations, while the unemployment rate held steady at 4.3%, leading to increased Treasury yields and heightened market expectations for a rate hike, negatively impacting stocks.
- Chip Stock Investment Opportunity: Jim Cramer highlighted that despite the tech sector's pullback, this presents a good opportunity to buy chip stocks, particularly Intel, which fell 6% on Friday, indicating that confidence in the sector remains strong.
- CrowdStrike Stock Decline: CrowdStrike's stock fell another 3.4% on Friday, with the CEO stating that expectations for earnings boosts from Anthropic's AI model are premature; Jim believes this pullback offers a buying opportunity for new investors, anticipating significant growth this quarter.
- Upcoming IPOs: SpaceX's IPO is set for next Friday, and although the S&P announced no index adjustments, Jim remains cautious about investors potentially selling existing holdings to make room for SpaceX, especially with Anthropic and OpenAI IPOs also on the horizon.
See More
Alvotech Resubmits U.S. Biosimilar Applications for AVT05 and AVT06
- Stock Surge: Alvotech (ALVO) shares spiked on Thursday following the company's announcement of the resubmission of U.S. marketing applications for biosimilars targeting Johnson & Johnson's (JNJ) Simponi and Regeneron's (REGN) Eylea, reflecting market optimism about its product prospects.
- Product Positioning: AVT05 is designed as an off-patent version of JNJ's arthritis therapy for both subcutaneous and intravenous administration, while AVT06 targets Regeneron's blockbuster eye therapy Eylea (aflibercept) 2 mg, indicating Alvotech's strategic positioning in the biopharmaceutical sector.
- Application Resubmission Context: The FDA previously denied the Biologics License Applications (BLA) for AVT05 and AVT06 due to manufacturing concerns, and the resubmission includes responses to an FDA Post-Application Action Letter and results from an FDA inspection completed in May 2026, demonstrating the company's commitment to compliance.
- Review Expectations: The resubmitted BLAs are expected to undergo a six-month review by the FDA, and a successful outcome could potentially open the U.S. market for Alvotech, further enhancing its growth potential in the biosimilar sector.
See More
